Valerie Juarez, APRN
Nurse Practitioner · Provo, UTNPI 1407967979
Payments from drug & device makers
Across 408 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$662
- Lilly USA, LLC$379
- Amgen$360
- AstraZeneca$359
- Astellas Pharma US Inc$279
- plus $3K from 36 others
What the payments were for
- Food & beverage$6,517100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 95 | $1,601 |
| Novo Nordisk | 43 | $662 |
| Lilly USA, LLC | 29 | $379 |
| Amgen | 22 | $360 |
| AstraZeneca | 24 | $359 |
| Astellas Pharma US Inc | 15 | $279 |
| Bayer | 17 | $260 |
| GSK | 15 | $244 |
| Boehringer Ingelheim | 14 | $242 |
| Merck | 12 | $196 |
| Daiichi Sankyo Inc. | 8 | $170 |
| Pfizer | 9 | $141 |
| E.r. Squibb & Sons, L.L.C. | 9 | $125 |
| Novartis | 6 | $113 |
| Sanofi-aventis U.S. LLC | 7 | $112 |
| Sunovion Pharmaceuticals Inc. | 10 | $102 |
| Actelion Pharmaceuticals US, Inc. | 5 | $101 |
| Sanofi Pasteur Inc. | 5 | $98 |
| Amarin Pharma, Inc. | 6 | $90 |
| Dexcom, Inc. | 5 | $87 |
| Phathom Pharmaceuticals, Inc. | 5 | $76 |
| Antares Pharma, Inc. | 5 | $65 |
| Edwards Lifesciences | 2 | $64 |
| Abbott | 3 | $61 |
| Arbor Pharmaceuticals, Inc. | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Avanir Pharmaceuticals, Inc. | 4 | $52 |
| Sumitomo Pharma America, Inc. | 5 | $52 |
| Johnson & Johnson | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Eisai Inc. | 3 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Biogen | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Heartflow, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Neurelis, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$122
How this compares
$6,517 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 244 | $226,207 |
| OzempicSemaglutide | 49 | $81,364 |
| JardianceEmpagliflozin | 52 | $66,800 |
| MounjaroTirzepatide | 44 | $47,649 |
| XareltoRivaroxaban | 24 | $33,414 |
| JanuviaSitagliptin Phosphate | 28 | $26,261 |
| MyrbetriqMirabegron | 26 | $25,377 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $22,855 |
| FarxigaDapagliflozin Propanediol | 19 | $15,146 |
| TrulicityDulaglutide | 13 | $14,199 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $12,722 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,657 |
| Omeprazole | 511 | $12,099 |
| Levothyroxine Sodium | 699 | $10,650 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $9,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $141 | $231,609257 claims |
| Novo NordiskOzempic | $662 | $81,36449 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $242 | $76,67173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $379 | $61,84857 claims |
| MerckJanuvia, Janumet | $196 | $34,50439 claims |
| Johnson & JohnsonXarelto | $39 | $33,41424 claims |
| AstraZenecaFarxiga, Symbicort | $359 | $27,86856 claims |
| Astellas Pharma US IncMyrbetriq | $279 | $25,37726 claims |
| AbbVieSynthroid | $1,601 | $3,38841 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Provo
- Clarene HansenProvo$11K
- Steven LarsenProvo$11K
- James BiesingerProvo$11K
- Tracy WilliamsProvo$9K
- Nancy MortensenProvo$5K
- April JensenProvo$5K
- Ann RogersonProvo$4K
- Nancy TrotterProvo$4K
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.